Get the Stockscreener App
7.75
1.31%
0.10
Pre-market:
7.75
Gyre Therapeutics Inc stock is traded at $7.75, with a volume of 36,237.
It is up +1.31% in the last 24 hours and up +3.89% over the past month.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$7.65
Open:
$7.61
24h Volume:
36,237
Relative Volume:
0.40
Market Cap:
$746.43M
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
82.89
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
-5.14%
1M Performance:
+3.89%
6M Performance:
-20.59%
1Y Performance:
-45.80%
1-Day Range:
$7.55
$7.79
1-Week Range:
$7.45
$8.37
52-Week Range:
$6.11
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(619) 949-3681
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Compare GYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.75 | 694.82M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | Jefferies | Buy |
| Aug-26-25 | Initiated | H.C. Wainwright | Buy |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
What recovery options are there for Gyre Therapeutics Inc.2025 Geopolitical Influence & Stepwise Swing Trade Plans - newser.com
Can Gyre Therapeutics Inc. stock sustain institutional interestTrade Volume Report & High Conviction Trade Alerts - newser.com
Trend analysis for Gyre Therapeutics Inc. this weekChart Signals & Daily Market Momentum Tracking - newser.com
Quantitative breakdown of Gyre Therapeutics Inc. recent moveWall Street Watch & Daily Oversold Bounce Ideas - newser.com
Analyzing Gyre Therapeutics Inc. with risk reward ratio chartsQuarterly Earnings Report & Risk Managed Investment Entry Signals - newser.com
What dividend safety score for Gyre Therapeutics Inc. stockTrade Risk Assessment & Long-Term Safe Investment Ideas - newser.com
Analyzing recovery setups for Gyre Therapeutics Inc. investorsGlobal Markets & Short-Term High Return Ideas - newser.com
Is this a good reentry point in Gyre Therapeutics Inc.Market Trend Report & AI Driven Price Forecasts - newser.com
Gyre Therapeutics (NASDAQ:GYRE) Shares Up 1.5%Time to Buy? - MarketBeat
Should I hold or sell Gyre Therapeutics Inc. stock in 20252025 Trade Ideas & Low Drawdown Trading Strategies - newser.com
How to integrate Gyre Therapeutics Inc. into portfolio analysis toolsJuly 2025 Catalysts & Daily Risk Controlled Trade Plans - newser.com
Published on: 2025-10-31 01:47:17 - newser.com
What institutional flow reveals about Gyre Therapeutics Inc.Dividend Hike & Expert Approved Momentum Trade Ideas - newser.com
Gyre Therapeutics, Inc. (GYRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Statistical indicators supporting Gyre Therapeutics Inc.’s strengthWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com
Gyre Therapeutics Inc Stock Analysis and ForecastStock Watchlist Updates & Free Explosive Earning Power - earlytimes.in
Is Manoj Vaibhav Gems N Jewellers Limited a Reliable Dividend Payer for Income InvestorsSwing Trading Watchlist & Superior Trading Portfolio - earlytimes.in
Published on: 2025-10-30 01:28:22 - newser.com
Published on: 2025-10-30 01:20:09 - newser.com
What momentum shifts mean for Gyre Therapeutics Inc.Short Setup & Accurate Buy Signal Alerts - newser.com
What technical signals suggest for Gyre Therapeutics Inc. stockWeekly Market Report & Community Driven Trade Alerts - Fundação Cultural do Pará
Leading vs lagging indicators on Gyre Therapeutics Inc. performanceTrade Volume Report & AI Powered Buy/Sell Recommendations - newser.com
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):